All In Biotech

Drug Trial Radar · NCT00003958

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma

Last checked: Nov 20, 2026Latest source record: Jun 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 702 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

702

Actual

Start

Sep 2002

Primary completion

Oct 2007

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.

Conditions

  • Adult Malignant Mesenchymoma
  • Adult Rhabdomyosarcoma
  • Alveolar Childhood Rhabdomyosarcoma
  • Childhood Malignant Mesenchymoma
  • Embryonal Childhood Rhabdomyosarcoma
  • Embryonal-botryoid Childhood Rhabdomyosarcoma
  • Nonmetastatic Childhood Soft Tissue Sarcoma
  • Previously Untreated Childhood Rhabdomyosarcoma
  • Stage I Adult Soft Tissue Sarcoma
  • Stage II Adult Soft Tissue Sarcoma
  • Stage III Adult Soft Tissue Sarcoma

Interventions

  • dactinomycinBiological

    Given IV

  • vincristine sulfateDrug

    Given IV

  • cyclophosphamideDrug

    Given IV

  • therapeutic conventional surgeryProcedure

    Undergo surgery

  • radiation therapyRadiation

    Undergo radiotherapy

  • topotecan hydrochlorideDrug

    Given IV

  • filgrastimBiological

    Given SC

  • sargramostimBiological

    Given SC

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term failure-free survival (FFS) between the two treatment groupsTime frame: Up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Oncology Group

    Arcadia, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.